Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues

• Published in: ACS chemical neuroscience 2024-04, Vol.15 (7), p.1469-1483
• Main Authors: Everett, James, Brooks, Jake, Tjendana Tjhin, Vindy, Lermyte, Frederik, Hands-Portman, Ian, Plascencia-Villa, Germán, Perry, George, Sadler, Peter J., O’Connor, Peter B., Collingwood, Joanna F., Telling, Neil D.
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Biochemistry & Molecular Biology; Brain - metabolism; Calcium - metabolism; Humans; Iron - metabolism; Neurosciences & Neurology; Pharmacology & Pharmacy; Plaque, Amyloid - metabolism
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.3c00756

The accumulation of amyloid plaques and increased brain redox burdens are neuropathological hallmarks of Alzheimer’s disease. Altered metabolism of essential biometals is another feature of Alzheimer’s, with amyloid plaques representing sites of disturbed metal homeostasis. Despite these observations, metal-targeting disease treatments have not been therapeutically effective to date. A better understanding of amyloid plaque composition and the role of the metals associated with them is critical. To establish this knowledge, the ability to resolve chemical variations at nanometer length scales relevant to biology is essential. Here, we present a methodology for the label-free, nanoscale chemical characterization of amyloid plaques within human Alzheimer’s disease tissue using synchrotron X-ray spectromicroscopy. Our approach exploits a C–H carbon absorption feature, consistent with the presence of lipids, to visualize amyloid plaques selectively against the tissue background, allowing chemical analysis to be performed without the addition of amyloid dyes that alter the native sample chemistry. Using this approach, we show that amyloid plaques contain elevated levels of calcium, carbonates, and iron compared to the surrounding brain tissue. Chemical analysis of iron within plaques revealed the presence of chemically reduced, low-oxidation-state phases, including ferromagnetic metallic iron. The zero-oxidation state of ferromagnetic iron determines its high chemical reactivity and so may contribute to the redox burden in the Alzheimer’s brain and thus drive neurodegeneration. Ferromagnetic metallic iron has no established physiological function in the brain and may represent a target for therapies designed to lower redox burdens in Alzheimer’s disease. Additionally, ferromagnetic metallic iron has magnetic properties that are distinct from the iron oxide forms predominant in tissue, which might be exploitable for the in vivo detection of amyloid pathologies using magnetically sensitive imaging. We anticipate that this label-free X-ray imaging approach will provide further insights into the chemical composition of amyloid plaques, facilitating better understanding of how plaques influence the course of Alzheimer’s disease.